Showing results (1-10 of 820) with videos related to
Sort By:
Pageof 82
Progress in Cardiovascular Diseases|June 22, 2002
Pharmacogenomics in cardiovascular diseasesDebabrata Mukherjee, Eric J TopolProgress in Cardiovascular Diseases|November 2, 2002
The role of low-molecular-weight heparin in cardiovascular diseasesDebabrata Mukherjee, Eric J TopolArthritis Research & Therapy|April 30, 2003
Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitorsDebabrata Mukherjee, Eric J TopolThe American Journal of Cardiology|December 17, 2003
Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients < or =40 years oldDebabrata Mukherjee, Amy Hsu, David J Moliterno, et al.Annals of Internal Medicine|February 2, 2026
In AF with drug-eluting stent for ≥1 y, NOACs were noninferior to NOAC + clopidogrel for a composite of adverse clinical events at 1 yDebabrata Mukherjee, Annals of Internal Medicine|August 18, 2020
After revascularization for PAD, rivaroxaban reduced vascular events with a small increase in major bleedingDebabrata MukherjeeAnnals of Internal Medicine|September 4, 2023
In HF, with or without PAD, dapagliflozin reduced a composite of worsening HF or CV death and did not increase amputationsDebabrata MukherjeeBiochemical Pharmacology|March 26, 2002
Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular eventsDebabrata MukherjeeCardiovascular & Hematological Agents in Medicinal Chemistry|December 15, 2012
Cardiovascular and Hematological Medicine in 2013 - Advances and InsightsDebabrata MukherjeeCongestive Heart Failure (Greenwich, Conn.)|April 11, 2008
Nonsteroidal anti-inflammatory drugs and the heart: what is the danger?Debabrata MukherjeePageof 82